Using the mTOR pathway strikes me as possibly too broad for the purpose of anti-aging: mTOR is a nutrient-sensing system and its activation triggers a lot of processes that most likely are not important for aging, such as micro-autophagy. There are other ways of triggering mitophagy, which is the key to delaying aging, such as using biguanides, and the relevant pharmaceutics are well-proven to have life-extending effects in humans, not just mouse data and preliminary immune system studies in humans.
On Sun, Dec 28, 2014 at 12:19 PM, Edouard Debonneuil wrote:
If they confirm it personally I’ll start taking low dose everolimus like one takes vitamin C. There is too much evidence in rodents (very robust treatment; the igf-1 related genetic interventions are also extremely robust), in human familial mutations and now with human treatments.
De : Natalie Jones À : Gerontology Research Group Envoyé le : Dimanche 28 décembre 2014 7h47Objet : Re: [GRG] Novartis story
Novartis made a big announcement in September in Basel: http://www.newscientist.com/article/mg22429894.000-everyday-drugs-could-give-extra-years-of-life.html?full=true#.VDXD_OfNdOj
I don’t know the details, but they are trying to replicate the study.
On Sat, Dec 27, 2014 at 4:48 PM, Louis Epstein wrote:
Pretty big on Google News now:http://www.webmd.com/healthy-aging/news/20141224/researchers-take-first-baby-step-toward-anti-aging-drughttp://www.usatoday.com/story/news/nation/2014/12/24/medications-anti-aging-benefits/20877811
The underlying studies are in Science Translational Medicine and PLOS
Genetics.Some familiar names are quoted…are any of the researchers
involved with GRG?
The World Trade Center towers MUST rise again,
at least as tall as before…or terror has triumphed.